Cushing syndrome
Rare disease
Yes
- Definition
- Cushing's syndrome (CS) encompasses a group of hormonal disorders caused by prolonged and high exposure levels to glucocorticoids that can be of either endogenous (adrenal cortex production) or exogenous (iatrogenic) origin.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Cushing syndrome
- Cushing syndrome
- hypercortisolism
- Cushing syndrome
- Cushing's syndrome
- cortisol Excess
- hyperadrenocorticism
- pituitary basophilism
- suprarenogenic syndrome
- adrenal hyperfunction resulting from pituitary ACTH excess
- ectopic adrenocorticotropic hormone syndrome
- nodular primary adrenocortical dysplasia
- Disease mechanisms
- Syndromic
- Severity
- Severe
- MONDO ID
- MONDO:0018912
- Parent condition
- MONDO:0002254
Related records
Broader conditions (4)
- Disease
- Disease by body system or component
- Human disease
- Syndromic disease
Narrower conditions (12)
- ACTH-dependent Cushing syndrome
- ACTH-independent adrenal Cushing syndrome, somatic
- ACTH-independent Cushing syndrome
- ACTH-independent macronodular adrenal hyperplasia 1
- ACTH-independent macronodular adrenal hyperplasia 2
- ACTH-independent macronodular adrenal hyperplasia 3
- Cushing disease due to pituitary adenoma
- Cushing syndrome due to cortisol-producing adrenocortical adenoma
- Cushing syndrome due to macronodular adrenal hyperplasia
- Ectopic Cushing syndrome
- Endogenous Cushing syndrome
- Exogenous Cushing syndrome
Trials (126)
- A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
- A Prospective Cohort Study for Patients With Adrenal Diseases
- A Single Center Randomized Controlled Study on the Promotion of Rapid Recovery
- A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome
- A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
- A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
- A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
- A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
- A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
- A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
- A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
- Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma
- Adolescence, Puberty, and Emotion Regulation
- Adrenal Tumors - Pathogenesis and Therapy
- Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal Tumors
- Alterations of Muscle Secretome Associated With Muscle Atrophy Caused by Glucocorticoids
- An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
- Appropriate Limit Value for 1 mg DST in Patients With Chronic Renal Failure
- Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
- Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome
Approved drugs (4)
- Ketoconazole
- Levoketoconazole
- Mifepristone
- Osilodrostat phosphate
Drugs in development (8)
- Edotreotide gallium GA-68 Phase 2
- Fluorodopa F 18 Phase 2
- Metyrapone Phase 3
- Nevanimibe hydrochloride Phase 2
- Osilodrostat Phase 2
- Pasireotide Phase 2
- Relacorilant Phase 3
- Tadalafil Phase 2